Progress in cell based assays for botulinum neurotoxin detection

Current Topics in Microbiology and Immunology

Volumn 364, Issue , 2013, Pages 257-285

  Pellett, Sabine ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Botulinum neurotoxins; Cell based assay; Detection assays; Neutralizing antibodies; Potency determination

Indexed keywords

BOTULINUM TOXIN; NEUROTRANSMITTER; NEUTRALIZING ANTIBODY; PROTEINASE; SNARE PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; NEUROTOXIN;

ANTIBODY DETECTION; ARTICLE; BIOASSAY; BOTULISM; CATALYSIS; CELL ASSAY; CELL DIFFERENTIATION; CELL LINE; CLOSTRIDIUM; CYTOSOL; DRUG POTENCY; ELECTRIC CONDUCTIVITY; EMBRYONIC STEM CELL; ENDOCYTOSIS; ENDOPEPTIDASE ASSAY; ENZYMATIC ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAVY CHAIN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL PROCEDURES; INCUBATION TIME; INTERMETHOD COMPARISON; LIGHT CHAIN; MEMBRANE BINDING; NERVE CELL; NERVE CELL CULTURE; NEURAL STEM CELL; NEURONAL CELL BASED ASSAY; NONHUMAN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN REFOLDING; PROTEIN TARGETING; PROTEIN TRANSPORT; SYNAPTIC INHIBITION; TOXICOKINETICS; TOXIN ANALYSIS; TOXIN DETECTION; TOXIN STRUCTURE; ANIMAL; ANIMAL TESTING ALTERNATIVE; CHEMISTRY; CLOSTRIDIUM BOTULINUM; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOUSE; REVIEW; TUMOR CELL LINE;

ANIMAL USE ALTERNATIVES; ANIMALS; ANTIBODIES, NEUTRALIZING; BIOLOGICAL ASSAY; BOTULINUM TOXINS; BOTULISM; CELL LINE, TUMOR; CLOSTRIDIUM BOTULINUM; EMBRYONIC STEM CELLS; HUMANS; IMMUNOASSAY; MICE; NEURONS; NEUROTOXINS; PROTEIN TRANSPORT; SNARE PROTEINS;

EID: 84875811081     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-33570-9-12     Document Type: Article

References (122)

1. Adler S, Bicker G, Bigalke H et al (2010) The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET expert meeting. Altern Lab Anim 38:315-330
2. Akaike N, Ito Y, Shin MC, Nonaka K, Torii Y, Harakawa T, Ginnaga A, Kozaki S, Kaji R (2010) Effects of A2 type botulinum toxin on spontaneous miniature and evoked transmitter release from the rat spinal excitatory and inhibitory synapses. Toxicon 56:1315-1326
3. Arnon SS, Schechter R, Inglesby TV et al (2001) Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070
4. Benatar MG, Willison HJ, Vincent A (1997) Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells. J Neuroimmunol 80:1-5
5. Bercsenyi K, Giribaldi F, Schiavo G (2012) The elusive compass of clostridial neurotoxins: deciding when and where to go? doi:10.1007/978-3-642- 33570-9-5
6. Bigalke H, Dimpfel W, Habermann E (1978) Suppression of 3H-acetylcholine release from primary nerve cell cultures by tetanus and botulinum-A toxin. Naunyn Schmiedebergs Arch Pharmacol 303:133-138
7. Bigalke H, Dreyer F, Bergey G (1985) Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture. Brain Res 360:318-324
8. Binz T (2012) Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission. doi:10.1007/978-3-642-33570-9-7
9. Binz T, Blasi J, Yamasaki S et al (1994) Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 269:1617-1620
10. Blasi J, Chapman ER, Link E et al (1993a) Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365:160-163
11. Blasi J, Chapman ER, Yamasaki S et al (1993b) Botulinum neurotoxin C1 blocks neurotransmitter release by means of cleaving HPC-1/syntaxin. EMBO J 12:4821-4828
12. Borodic G (2007) Botulinum toxin, immunologic considerations with long-term repeated use, with emphasis on cosmetic applications. Facial Plast Surg Clin North Am 15:11-16
13. Borodic GE, Duane D, Pearce B et al (1995) Antibodies to botulinum toxin. Neurology 45:204
14. Brewer GJ (1995) Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. J Neurosci Res 42:674-683
15. Brewer GJ, Torricelli JR, Evege EKetal (1993) Optimized survival of hippocampal neurons in B27-supplemented neurobasal, a new serum-free medium combination. J Neurosci Res 35:567-576
16. Cartee TV, Monheit GD (2011) An overview of botulinum toxins: past, present, and future. Clin Plast Surg 38:409-426
17. Conway JO, Sherwood LJ, Collazo MT et al (2010) Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. PLoS ONE 5:e8818
18. Cordivari C, Misra VP, Vincent A et al (2006) Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21:1737-1741
19. Dong M, Liu H, Tepp WH et al (2008) Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19:5226-5237
20. Dong M, Richards DA, Goodnough MC et al (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 162:1293-1303
21. Dong M, Tepp WH, Johnson EA et al (2004) Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc Natl Acad Sci U S A 101:14701-14706
22. Dong M, Tepp WH, Liu H et al (2007) Mechanism of botulinum neurotoxin B and G entry into hippocampal neurons. J Cell Biol 179:1511-1522
23. Dong M, Yeh F, Tepp WH et al (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596
24. Dorner MB, Schulz KM, Kull S (2012) Complexity of botulinum neurotoxins: challenges for detection technology. doi:10.1007/978-3-642-33570-9-11
25. Dressler D (2004) Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord 19(Suppl 8):S92-S100
26. Dressler D, Benecke R (2007) Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 29:1761-1768
27. Dressler D, Bigalke H (2002) Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov Disord 17:170-173
28. Dressler D, Lange M, Bigalke H (2005) Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord 20:1617-1619
29. Dressler D, Wohlfahrt K, Meyer-Rogge E et al (2010) Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 36(Suppl 4):2182-2187
30. Duggan MJ, Quinn CP, Chaddock JA et al (2002) Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 277:34846-34852
31. Eleopra R, Tugnoli V, Quatrale R et al (2004) Different types of botulinum toxin in humans. Mov Disord 19(Suppl 8):S53-S59
32. Eleopra R, Tugnoli V, Rossetto O et al (1998) Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256:135-138
33. Evidente VG, Adler CH (2010) An update on the neurologic applications of botulinum toxins. Curr Neurol Neurosci Rep 10:338-344
34. Fischer A (2012) Synchronized chaperone function of botulinum neurotoxin domains mediates light chain translocation into neurons. doi:10.1007/978-3-642- 33570-9-6
35. Fischer A, Montal M (2007a) Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem 282:29604-29611
36. Fischer A, Montal M (2007b) Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci U S A 104:10447-10452
37. Fischer A, Nakai Y, Eubanks LM et al (2009) Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A 106:1330-1335
38. Flynn TC (2004) Myobloc. Dermatol Clin 22:207-211 vii
39. Gimenez DF, Gimenez JA (1995) The typing of botulinal neurotoxins. Int J Food Microbiol 27:1-9
40. Hatheway CL (1988) Botulism. In: Balows A, Hausler WH, Ohashi M, Turano MA (eds) Laboratory diagnosis of infectious diseases: principles and practice, vol 1. Springer, New York, pp 111-133
41. Hill KK, Smith TJ (2012) Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. doi:10.1007/978-3-642-33570-9-1
42. Hu BY, Zhang SC (2010) Directed differentiation of neural-stem cells and subtype-specific neurons from hESCs. Methods Mol Biol 636:123-137
43. Johnson EA, Montecucco C (2008) Chapter 11 Botulism. In: Engel Andrew G (ed) Handbook of clinical neurology, vol 91. Elsevier, pp 333-368
44. Jones RG, Alsop TA, Hull R et al (2006) Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon 48:246-254
45. Jones RG, Liu Y, Halls C et al (2011) Release of proteolytic activity following reduction in therapeutic human serum albumin containing products: detection with a new neoepitope endopeptidase immunoassay. J Pharm Biomed Anal 54:74-80
46. Kalb SR, Baudys J, Egan C et al (2011) Different substrate recognition requirements for cleavage of synaptobrevin-2 by Clostridium baratii and Clostridium botulinum type F neurotoxins. Appl Environ Microbiol 77:1301-1308
47. Keller JE, Cai F, Neale EA (2004) Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 43:526-532
48. Keller JE, Neale EA (2001) The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A. J Biol Chem 276:13476-13482
49. Keller JE, Neale EA, Oyler G et al (1999) Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett 456:137-142
50. Kessler KR, Benecke R (1997) The EBD test-a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12:95-99
51. Kiris E, Nuss JE, Burnett JC et al (2011) Embryonic stem cell-derived motoneurons provide a highly sensitive cell culture model for botulinum neurotoxin studies, with implications for high-throughput drug discovery. Stem Cell Res 6:195-205
52. Kivell BM, McDonald FJ, Miller JH (2001) Method for serum-free culture of late fetal and early postnatal rat brainstem neurons. Brain Res Brain Res Protoc 6:91-99
53. Kohno K, Kawakami T, Hiruma H (2005) Effects of soluble laminin on organelle transport and neurite growth in cultured mouse dorsal root ganglion neurons: difference between primary neurites and branches. J Cell Physiol 205:253-261
54. Lacy DB, Tepp W, Cohen AC et al (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 5:898-902
55. Lee JO, Rosenfield J, Tzipori S et al (2008) M17 human neuroblastoma cell as a cell model for investigation of botulinum neurotoxin A activity and evaluation of BoNT/A specific antibody. The Botulinum J 1:135-152
56. Liu YY, Rigsby P, Sesardic D et al (2012) A functional dual-coated (FDC) microtitre plate method to replace the botulinum toxin LD (50) test. Anal Biochem 425:28-35
57. Macdonald TE, Helma CH, Shou Y et al (2011) Analysis of Clostridium botulinum serotype E strains by using multilocus sequence typing, amplified fragment length polymorphism, variable-number tandem-repeat analysis, and botulinum neurotoxin gene sequencing. Appl Environ Microbiol 77:8625-8634
58. McInnes C, Dolly JO (1990) Ca2 (+)-dependent noradrenaline release from permeabilised PC12 cells is blocked by botulinum neurotoxin A or its light chain. FEBS Lett 261:323-326
59. 2+. J Neurochem 56:86-94
60. McNutt P, Celver J, Hamilton T et al (2011) Embryonic stem cell-derived neurons are a novel, highly sensitive tissue culture platform for botulinum research. Biochem Biophys Res Commun 405:85-90
61. Montal M (2010) Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem 79:591-617
62. Montecucco C (1986) How do tetanus and botulinum toxins bind to neuronal membranes? Trends Biochem Sci 11:314-317
63. Muller K, Mix E, Adib Saberi F et al (2009) Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm 116:579-585
64. Nishiki T, Kamata Y, Nemoto Y et al (1994) Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 269:10498-10503
65. Nuss JE, Ruthel G, Tressler LE et al (2010) Development of cell-based assays to measure botulinum neurotoxin serotype A activity using cleavage-sensitive antibodies. J Biomol Screen 15:42-51
66. Parnas D, Linial M (1995) Cholinergic properties of neurons differentiated from an embryonal carcinoma cell-line (P19). Int J Dev Neurosci 13:767-781
67. Peck MW (2009) Biology and genomic analysis of Clostridium botulinum. Adv Microb Physiol 55(183-265):320
68. Pellett S, Du ZW, Pier CL et al (2011) Sensitive and quantitative detection of botulinum neurotoxin in neurons derived from mouse embryonic stem cells. Biochem Biophys Res Commun 404:388-392
69. Pellett S, Tepp WH, Clancy CM et al (2007) A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett 581:4803-4808
70. Pellett S, Tepp WH, Toth SI et al (2010) Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J Pharmacol Toxicol Methods 61:304-310
71. Peng L, Berntsson RP, Tepp WH et al. (2012) Botulinum neurotoxin D-C uses synaptotagmin I/II as receptors and human synaptotagmin II is not an effective receptor for type B, D-C, and G toxins. J Cell Sci. March 2012 epub ahead of print
72. Peng L, Tepp WH, Johnson EA et al (2011) Botulinum neurotoxin D uses synaptic vesicle protein SV2 and gangliosides as receptors. PLoS Pathog 7:e1002008
73. Pickett A, Perrow K (2011) Towards new uses of botulinum toxin as a novel therapeutic tool. Toxins (Basel) 3:63-81
74. Pier CL, Chen C, Tepp WH et al (2011) Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett 585:199-206
75. Purkiss JR, Friis LM, Doward S et al (2001) Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology 22:447-453
76. Raphael BH, Choudoir MJ, Luquez C et al (2010) Sequence diversity of genes encoding botulinum neurotoxin type F. Appl Environ Microbiol 76:4805-4812
77. Rasetti-Escargueil C, Jones RG, Liu Y, Sesardic D (2009) Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 53:503-511
78. Rasetti-Escargueil C, Machado CB, Preneta-Blanc R et al (2011a) Enhanced sensitivity to botulinum type A neurotoxin of human neuroblastoma SH-SY5Y cells after differentiation into mature neuronal cells. The Botulinum J 2:30-48
79. Rasetti-Escargueil C, Liu Y, Rigsby P et al (2011b) Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon 57:1008-1016
80. Ravni A, Bourgault S, Lebon A et al (2006) The neurotrophic effects of PACAP in PC12 cells: control by multiple transduction pathways. J Neurochem 98:321-329
81. Ray P (1993) Botulinum toxin A inhibits acetylcholine release from cultured neurons in vitro. In Vitro Cell Dev Biol Anim 29 A: 456-460
82. Rummel A (2012) Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. doi:10.1007/978-3-642-33570-9-4
83. Rummel A, Hafner K, Mahrhold S et al (2009) Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J Neurochem 110:1942-1954
84. Rummel A, Karnath T, Henke T et al (2004) Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J Biol Chem 279:30865-30870
85. Rummel A, Mahrhold S, Bigalke H et al (2011) Exchange of the H (CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin. FEBS J 278:4506-4515
86. Saadi RA, He K, Hartnett KA et al (2012) SNARE-dependent upregulation of potassium chloride co-transporter 2 activity after metabotropic zinc receptor activation in rat cortical neurons in vitro. Neuroscience 210:38-46
87. Schantz EJ, Kautter DA (1978) Standardized assay for Clostridium botulinum toxins. J Assoc Official Anal Chem 61:96-99
88. Schantz EJ, Johnson EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56:80-99
89. Schiavo G, Benfenati F, Poulain B et al (1992) Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359:832-835
90. Schiavo G, Malizio C, Trimble WS et al (1994) Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J Biol Chem 269:20213-20216
91. Schiavo G, Matteoli M, Montecucco C (2000) Neurotoxins affecting neuroexocytosis. Physiol Rev 80:717-766
92. Schiavo G, Shone CC, Bennett MK et al (1995) Botulinum neurotoxin type C cleaves a single Lys-Ala bond within the carboxyl-terminal region of syntaxins. J Biol Chem 270:10566-10570
93. Schiavo G, Shone CC, Rossetto O et al (1993) Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 268:11516-11519
94. Sesardic D, Jones RG, Leung T et al (2004) Detection of antibodies against botulinum toxins. Mov Disord 19(Suppl 8):S85-S91
95. Sesardic D, Das RG (2007) Alternatives to the LD50 assay for botulinum toxin potency testing: strategies and progress towards refinement, reduction and replacement. Special Issue 14:581-585
96. Sesardic D, Leung T, Gaines Das R (2003) Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals 31:265-276
97. Sheridan RE, Smith TJ, Adler M (2005) Primary cell culture for evaluation of botulinum neurotoxin antagonists. Toxicon 45:377-382
98. Shone CC, Melling J (1992) Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem 207:1009-1016
99. Smith TJ, Lou J, Geren IN et al (2005) Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun 73:5450-5457
100. Solomon HM, Lilly T (2001) Clostridium botulinum. In: BAM bacteriological analytical manual U. S. Food and Drug Administration, Chapter 17, 8th edn. Revision A
101. Stahl AM, Ruthel G, Torres-Melendez E et al (2007) Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. J Biomol Screen 12:370-377
102. Strotmeier J, Willjes G, Binz T et al (2012) Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 586:310-313
103. Swaminathan S (2011) Molecular structures and functional relationships in clostridial neurotoxins. FEBS J 278:4467-4485
104. Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872
105. Tegenge MA, Bohnel H, Gessler F et al (2012) Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A. Cell Mol Neurobiol 32:1021-1029
106. Truong DD, Stenner A, Reichel G (2009) Current clinical applications of botulinum toxin. Curr Pharm Des 15:3671-3680
107. Tsukamoto K, Arimitsu H, Ochi S et al. (2012) P19 embryonal carcinoma cells exhibit high sensitivity to botulinum type C and D/C mosaic neurotoxins. Microbiol Immunol July 2012 epub ahead of print
108. Uemura M, Refaat MM, Shinoyama M et al (2010) Matrigel supports survival and neuronal differentiation of grafted embryonic stem cell-derived neural precursor cells. J Neurosci Res 88:542-551
109. Ullrich B, Li C, Zhang JZ, McMahon H et al (1994) Functional properties of multiple synaptotagmins in brain. Neuron 13:1281-1291
110. Verderio C, Grumelli C, Raiteri L et al (2007) Traffic of botulinum toxins A and E in excitatory and inhibitory neurons. Traffic 8:142-153
111. Welch MJ, Purkiss JR, Foster KA (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245-258
112. Whitemarsh RC, Strathman MJ, Chase LG et al (2012) Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci 126:426-435
113. Wichterle H, Peljto M (2008) Differentiation of mouse embryonic stem cells to spinal motor neurons. Curr Protoc Stem Cell Biol Chapter 1: Unit 1H.1.1-1H.1.9
114. Wilder-Kofie TD, Luquez C, Adler M et al (2011) An alternative in vivo method to refine the mouse bioassay for botulinum toxin detection. Comp Med 61:235-242
115. Williamson LC, Halpern JL, Montecucco C et al (1996) Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa. J Biol Chem 271:7694-7699
116. Xie C, Markesbery WR, Lovell MA (2000) Survival of hippocampal and cortical neurons in a mixture of MEM+ and B27-supplemented neurobasal medium. Free Radic Biol Med 28:665-672
117. Yaguchi T, Nishizaki T (2010) Extracellular high K+ stimulates vesicular glutamate release from astrocytes by activating voltage-dependent calcium channels. J Cell Physiol 225:512-518
118. Yamasaki S, Baumeister A, Binz T et al (1994) Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem 269:12764-12772
119. Yowler BC, Kensinger RD, Schengrund CL (2002) Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. J Biol Chem 277:32815-32819
120. Yu J, Vodyanik MA, Smuga-Otto K et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920
121. Zhang SC (2006) Neural subtype specification from embryonic stem cells. Brain Pathol 16:132-142
122. Zhu H, Wang J, Jacky B P S et al (2010) Cells useful for immuno-based botulinum toxin serotype A activity assays. US-Patent 12/722801 (Allergan Inc) CA, USA